Available compounds
| Drug | Tumor type | Target | Status inclusion |
|---|---|---|---|
| Amivantamab | Non-small cell lung cancer | EGRF exon 20 insertion mutation | Open |
| Capmatinib | Non-small cell lung cancer | MET exon 14 skipping mutations | Closed |
| Cemiplimab | Cutaneous squamous cell carcinoma | n.a. | Closed |
| Entrectinib | All | NTRK gene fusions | Closed |
| Larotrectinib | All | NTRK gene fusions | Closed |
| Selpercatinib | Non-small cell lung cancer | RET fusions | Closed |
| Selpercatinib | Medullary thyroid cancer | RET mutations | Closed |
| Selpercatinib | Tumor agnostic | RET fusions | Open |
| Tepotinib | Non-small cell lung cancer | MET exon 14 skipping mutations | Closed |